Skip to main content
. 2021 Jan 28;10:616094. doi: 10.3389/fonc.2020.616094

Table 1.

Patient demographics.

All recurrence (n = 349) Recur within 2 years (n = 213) Recur after 2 years (n = 136) P-value
Survival after recurrence: months (median, IQR) 11.2 (5.7–22.3) 10.2 (5.2–19.9) 14.3 (6.6–32.6) 0.026
Age: years (mean ± SD) 55.4 ± 8.6 55.1 ± 8.7 54.1 ± 8.4 0.295
Male (n, %) 295 (84.5) 181 (85) 114 (83.8) 0.890
Cirrhosis (n, %) 314 (90.0) 189 (88.7) 125 (91.9) 0.434
Diabetes mellitus (n, %) 79 (22.6) 51 (23.9) 28 (20.6) 0.549
Hyperlipidemia (n, %) 36 (10.3) 22 (10.3) 14 (10.3) 1.000
Alcohol use (n, %) 16 (4.6) 13 (6.1) 3 (2.2) 0.151
HBV (n, %) 262 (75.1) 163 (76.5) 99 (72.8) 0.510
HBV-medication use before transplant (n, %) 173 (49.6) 104 (48.8) 69 (50.7) 0.812
HCV (n, %) 150 (43.0) 97 (45.5) 53 (39.0) 0.272
HCV-medication use before transplant (n, %) 39 (11.2) 20 (9.4) 19 (14.0) 0.250
Living donor (n, %) 266 (76.2) 163 (76.5) 103 (75.7) 0.968
Transplantation period (n, %) < 0.001
 Before 2008 112 (32.1) 55 (25.8) 57 (41.9)
 2009–2012 134 (38.4) 71 (33.3) 63 (46.3)
 After 2013 103 (29.5) 87 (40.9) 16 (11.8)

IQR, interquartile range; SD, standard deviation.